ChloroquineV1, Main, Exploration, bibRecord, 000C08

Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.

Identifieur interne : 000C08 ( Main/Exploration ); précédent : 000C07; suivant : 000C09

Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.

Auteurs : Laurel M. Schunselaar [Pays-Bas] ; Kim Monkhorst [Pays-Bas] ; Vincent Van Der Noort [Pays-Bas] ; Ruud Wijdeven [Pays-Bas] ; Dennis Peters [Pays-Bas] ; Wilbert Zwart [Pays-Bas] ; Jacques Neefjes [Pays-Bas] ; Paul Baas [Pays-Bas]

Source :

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [ 1556-1380 ] ; 2018.

RBID : pubmed:29959059

Descripteurs français

KwdFr :
- Analyse de survie, Anticorps monoclonaux (métabolisme), Glycoprotéines (métabolisme), Humains, Mésothéliome (anatomopathologie), Mésothéliome (mortalité), Mésothéliome (traitement médicamenteux), Résultat thérapeutique, Trophoblastes (métabolisme), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (mortalité), Tumeurs du poumon (traitement médicamenteux).
MESH :
- anatomopathologie : Mésothéliome, Tumeurs du poumon.
- mortalité : Mésothéliome, Tumeurs du poumon.
- métabolisme : Anticorps monoclonaux, Glycoprotéines, Trophoblastes.
- traitement médicamenteux : Mésothéliome, Tumeurs du poumon.
- Analyse de survie, Humains, Résultat thérapeutique.

English descriptors

KwdEn :
- Antibodies, Monoclonal (metabolism), Glycoproteins (metabolism), Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (mortality), Lung Neoplasms (pathology), Mesothelioma (drug therapy), Mesothelioma (mortality), Mesothelioma (pathology), Progression-Free Survival, Survival Analysis, Treatment Outcome, Trophoblasts (metabolism).
MESH :
- chemical , metabolism : Antibodies, Monoclonal, Glycoproteins.
- drug therapy : Lung Neoplasms, Mesothelioma.
- metabolism : Trophoblasts.
- mortality : Lung Neoplasms, Mesothelioma.
- pathology : Lung Neoplasms, Mesothelioma.
- Humans, Progression-Free Survival, Survival Analysis, Treatment Outcome.

Abstract

The prognosis for patients with mesothelioma is poor, which prompts the need for the development of better treatment options. Antibody drug conjugates (ADCs) are gaining interest as a therapeutic strategy in mesothelioma. Trophoblast glycoprotein (5T4) is an oncofetal protein overexpressed in mesothelioma with low expression in normal tissue and therefore a good candidate for ADC treatment. Here, we evaluated and manipulated 5T4 as a suitable antigen for ADC targeted therapy in patients with mesothelioma.

DOI: 10.1016/j.jtho.2018.06.008
PubMed: 29959059

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.</title>
<author><name sortKey="Schunselaar, Laurel M" sort="Schunselaar, Laurel M" uniqKey="Schunselaar L" first="Laurel M" last="Schunselaar">Laurel M. Schunselaar</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Monkhorst, Kim" sort="Monkhorst, Kim" uniqKey="Monkhorst K" first="Kim" last="Monkhorst">Kim Monkhorst</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Pathology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Der Noort, Vincent" sort="Van Der Noort, Vincent" uniqKey="Van Der Noort V" first="Vincent" last="Van Der Noort">Vincent Van Der Noort</name>
<affiliation wicri:level="3"><nlm:affiliation>Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Biometrics Department, Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wijdeven, Ruud" sort="Wijdeven, Ruud" uniqKey="Wijdeven R" first="Ruud" last="Wijdeven">Ruud Wijdeven</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peters, Dennis" sort="Peters, Dennis" uniqKey="Peters D" first="Dennis" last="Peters">Dennis Peters</name>
<affiliation wicri:level="3"><nlm:affiliation>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zwart, Wilbert" sort="Zwart, Wilbert" uniqKey="Zwart W" first="Wilbert" last="Zwart">Wilbert Zwart</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Neefjes, Jacques" sort="Neefjes, Jacques" uniqKey="Neefjes J" first="Jacques" last="Neefjes">Jacques Neefjes</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baas, Paul" sort="Baas, Paul" uniqKey="Baas P" first="Paul" last="Baas">Paul Baas</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: p.baas@nki.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29959059</idno>
<idno type="pmid">29959059</idno>
<idno type="doi">10.1016/j.jtho.2018.06.008</idno>
<idno type="wicri:Area/PubMed/Corpus">000100</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000100</idno>
<idno type="wicri:Area/PubMed/Curation">000100</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000100</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000081</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000081</idno>
<idno type="wicri:Area/Ncbi/Merge">000453</idno>
<idno type="wicri:Area/Ncbi/Curation">000453</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000453</idno>
<idno type="wicri:Area/Main/Merge">000C08</idno>
<idno type="wicri:Area/Main/Curation">000C08</idno>
<idno type="wicri:Area/Main/Exploration">000C08</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.</title>
<author><name sortKey="Schunselaar, Laurel M" sort="Schunselaar, Laurel M" uniqKey="Schunselaar L" first="Laurel M" last="Schunselaar">Laurel M. Schunselaar</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Monkhorst, Kim" sort="Monkhorst, Kim" uniqKey="Monkhorst K" first="Kim" last="Monkhorst">Kim Monkhorst</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Pathology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Der Noort, Vincent" sort="Van Der Noort, Vincent" uniqKey="Van Der Noort V" first="Vincent" last="Van Der Noort">Vincent Van Der Noort</name>
<affiliation wicri:level="3"><nlm:affiliation>Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Biometrics Department, Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wijdeven, Ruud" sort="Wijdeven, Ruud" uniqKey="Wijdeven R" first="Ruud" last="Wijdeven">Ruud Wijdeven</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peters, Dennis" sort="Peters, Dennis" uniqKey="Peters D" first="Dennis" last="Peters">Dennis Peters</name>
<affiliation wicri:level="3"><nlm:affiliation>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zwart, Wilbert" sort="Zwart, Wilbert" uniqKey="Zwart W" first="Wilbert" last="Zwart">Wilbert Zwart</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Neefjes, Jacques" sort="Neefjes, Jacques" uniqKey="Neefjes J" first="Jacques" last="Neefjes">Jacques Neefjes</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baas, Paul" sort="Baas, Paul" uniqKey="Baas P" first="Paul" last="Baas">Paul Baas</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: p.baas@nki.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</title>
<idno type="eISSN">1556-1380</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (metabolism)</term>
<term>Glycoproteins (metabolism)</term>
<term>Humans</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (mortality)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Mesothelioma (drug therapy)</term>
<term>Mesothelioma (mortality)</term>
<term>Mesothelioma (pathology)</term>
<term>Progression-Free Survival</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
<term>Trophoblasts (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie</term>
<term>Anticorps monoclonaux (métabolisme)</term>
<term>Glycoprotéines (métabolisme)</term>
<term>Humains</term>
<term>Mésothéliome (anatomopathologie)</term>
<term>Mésothéliome (mortalité)</term>
<term>Mésothéliome (traitement médicamenteux)</term>
<term>Résultat thérapeutique</term>
<term>Trophoblastes (métabolisme)</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (mortalité)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Glycoproteins</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mésothéliome</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term>
<term>Mesothelioma</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Trophoblasts</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Lung Neoplasms</term>
<term>Mesothelioma</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Mésothéliome</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Glycoprotéines</term>
<term>Trophoblastes</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term>
<term>Mesothelioma</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mésothéliome</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Progression-Free Survival</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term>
<term>Humains</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The prognosis for patients with mesothelioma is poor, which prompts the need for the development of better treatment options. Antibody drug conjugates (ADCs) are gaining interest as a therapeutic strategy in mesothelioma. Trophoblast glycoprotein (5T4) is an oncofetal protein overexpressed in mesothelioma with low expression in normal tissue and therefore a good candidate for ADC treatment. Here, we evaluated and manipulated 5T4 as a suitable antigen for ADC targeted therapy in patients with mesothelioma.</div>
</front>
</TEI>
<affiliations><list><country><li>Pays-Bas</li>
</country>
<region><li>Hollande-Méridionale</li>
<li>Hollande-Septentrionale</li>
</region>
<settlement><li>Amsterdam</li>
<li>Leyde</li>
</settlement>
</list>
<tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Schunselaar, Laurel M" sort="Schunselaar, Laurel M" uniqKey="Schunselaar L" first="Laurel M" last="Schunselaar">Laurel M. Schunselaar</name>
</region>
<name sortKey="Baas, Paul" sort="Baas, Paul" uniqKey="Baas P" first="Paul" last="Baas">Paul Baas</name>
<name sortKey="Monkhorst, Kim" sort="Monkhorst, Kim" uniqKey="Monkhorst K" first="Kim" last="Monkhorst">Kim Monkhorst</name>
<name sortKey="Neefjes, Jacques" sort="Neefjes, Jacques" uniqKey="Neefjes J" first="Jacques" last="Neefjes">Jacques Neefjes</name>
<name sortKey="Peters, Dennis" sort="Peters, Dennis" uniqKey="Peters D" first="Dennis" last="Peters">Dennis Peters</name>
<name sortKey="Van Der Noort, Vincent" sort="Van Der Noort, Vincent" uniqKey="Van Der Noort V" first="Vincent" last="Van Der Noort">Vincent Van Der Noort</name>
<name sortKey="Wijdeven, Ruud" sort="Wijdeven, Ruud" uniqKey="Wijdeven R" first="Ruud" last="Wijdeven">Ruud Wijdeven</name>
<name sortKey="Zwart, Wilbert" sort="Zwart, Wilbert" uniqKey="Zwart W" first="Wilbert" last="Zwart">Wilbert Zwart</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C08 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C08 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29959059
   |texte=   Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29959059" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

Serveur d'exploration Chloroquine

Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.

Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.